Programs and Agendae of past, current and upcoming meetings
The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects.
In July 2012, the European Commission prepared a proposal for the European Parliament, which is not a directive but a regulation. Couching the legislation as a regulation rather than a directive will ensure that the new rules, once finalized and adopted, will have an immediate and binding impact across the EU, avoiding ...
New trial: A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
The 9th Information Letter is available online. For the first time, this issue contains summaries of the most important clinical results from oral presentations of the 54th ASH Annual Meeting which were selected and summarized by ELN experts.